BCD-066 (darbepoetin alfa biosimilar) / Biocad - LARVOL DELTA

Biocad’s biosimilar of darbepoetin alfa will be available at the end of 2018 (GMP news) - "The drug will be commercially available at the end of 2018 and, in 2021, the company plans to launch its own new innovative medicine for the treatment of anemia in patients with renal failure and cancer."

Biosimilar launch

Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients (clinicaltrials.gov) - P3; N=196; Completed; Sponsor: Biocad; Recruiting ➔ Completed

Clinical • Trial completion